By automating and digitizing critical processes, Ori’s platform is designed to streamline manufacturing workflows and overcome bottlenecks that limit patient access.
The partnership integrates Asimov’s CHO Edge platform, which uses synthetic biology and AI to optimize Chinese hamster ovary cell lines for antibody and protein production.
Lifecore will oversee the technology transfer of the drug’s fill-finish process, conduct gap assessments, and provide a pilot batch as part of the collaboration.
The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing's print and online coverage.
